NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/07/2026
Voltar para busca
Dado oficial do USPTO
KALDENN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
33
Atualização mais recente
09/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 10
Data de depósito
14/05/2024
Data de registro
12/08/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
12/08/2025
Última transação
09/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
FR
Examinador
OAKES, JEFFREY ALLEN
Unidade examinadora
O10
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
N. P. (pessoa física)
Representantes
Jeffrey H. Handelsman Greenblum & Bernstein, P.L.C.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical substanceschemical materials and chemical products for use in medicine productionchemical additives and active chemical ingredients for use in the manufacture of radiopharmaceutical preparations and pharmaceuticals for detecting and treating coronary diseases and coronary artery diseases; chemical substanceschemical preparations and chemical products for use in radiopharmaceutical product manufacturechemical additives and active chemical ingredients for use in the manufacture of radiopharmaceutical preparations and pharmaceuticals for detecting and treating myocardial ischaemia; active chemical ingredients for use in manufacture of radiopharmaceutical preparations against cancer; diagnostic preparations for scientific use or for research; diagnostic reagents for scientific use or for research; radioactive preparations for laboratory use for scientific purposes; contrast agents for molecular imaging other than for medical use; rubidium; strontium
Classe 5
Radiopharmaceutical productsradioactive substances for use in nuclear medicine; radioactive products for medical useradioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; radioactive substances for medical use; isotopes for medical use; radiopharmaceutical preparations for medical use made from radiopharmaceutical generatorsfor the detection and treatment of cancerscoronary diseasescoronary artery diseasesheart diseases and myocardial ischaemia; diagnostic radiopharmaceutical preparations; reagents and substances for medical diagnostic purposes; diagnostic biomarking reagents for medical use; contrast products being media for use with medical imaging equipment; cardiovascular medicines used in myocardial infarction treatment; contrast agents being media for use with molecular imaging equipment for medical use
Classe 10
Radiopharmaceutical generators for medical use being medical generators specially adapted for medicaldiagnostic and therapeutic purposesnamely for use in the production and transportation of nuclear medicinesradioactive substances for medical purposesradiopharmaceutical products and radiopharmaceutical medicines; radioactive and radiopharmaceutical product generators for medical use being medical generators specially adapted for medical nuclear medicine purposesnamely for use in the production and transportation of nuclear medicinesradioactive substances for medical purposesradiopharmaceutical products and radiopharmaceutical medicines; rubidium-82 generators for medical use being medical generators specially adapted for medicaldiagnostic and therapeutic purposesnamely for use in the production and transportation of nuclear medicinesradioactive substances for medical purposesradiopharmaceutical products and radiopharmaceutical medicines; medication injectors for medical usemedical fluid injectors and injection devices for pharmaceuticals and radiopharmaceutical products; radiopharmaceutical medicine injectors being injection devices; radioactive and radiopharmaceutical product injectors for medical use being injection devices for pharmaceuticalsradioactive products and radiopharmaceutical products; automatic injectors being injection devices for administering radiopharmaceutical products; injectors of rubidium-82 to patients for medical usemedical fluid injectors and injection devices for pharmaceuticalsradioactive products and radiopharmaceutical products; magnetic resonance tomography apparatusmagnetic resonance imaging apparatus for medical purposes; medical equipmentcomputed tomography apparatus; tomographic scanners for nuclear medicineX-ray CT scanners; medical apparatus for diagnosing suspected heart attacks
Publicações
Histórico de despachos e eventos da marca no USPTO.
33 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
26/03/2026
NREP
NEW REPRESENTATIVE AT IB RECEIVED
19/03/2026
FICS
FINAL DISPOSITION NOTICE SENT TO IB
21/02/2026
FIMP
FINAL DISPOSITION PROCESSED
21/02/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
12/02/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
27/01/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
27/01/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/11/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/08/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
12/08/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
24/06/2025
PUBO
PUBLISHED FOR OPPOSITION
24/06/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/06/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
21/05/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/05/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/05/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
15/05/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
15/05/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
15/05/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
15/05/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
15/05/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
15/05/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
15/05/2025
RFNT
REFUSAL PROCESSED BY IB
29/12/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/12/2024
RFRR
REFUSAL PROCESSED BY MPU
12/12/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
28/11/2024
CNRT
NON-FINAL ACTION WRITTEN
27/11/2024
DOCK
ASSIGNED TO EXAMINER
26/11/2024
MAFR
APPLICATION FILING RECEIPT MAILED
03/09/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/09/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
29/08/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace KALDENN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.